Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2965-2973

  Kityo, C ^a   Walker, A S ^b   Dickinson, L ^c,d   Lutwama, F ^e   Kayiwa, J ^a   Ssali, F ^a   Nalumenya, R ^e   Tumukunde, D ^a   Munderi, P ^f   Reid, A ^g   Gilks, C F ^h   Gibb, D M ^b   Khoo, S ^c  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e Infectious Diseases Institute   (Uganda)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; BENZOXAZINE DERIVATIVE; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UGANDA; AGED; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIV INFECTIONS; MIDDLE AGED;

ADULT; AGED; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; NEVIRAPINE; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; UGANDA;

EID: 77953734136     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01198-09     Document Type: Article

References (16)

1. Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, and D. Burger. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
2. Chiu, Y., M. King, J. Li, C. Klein, and G. Hanna. 2007. Trough lopinavir concentrations do not predict virologic response to lopinavir/ritonavir-based three-drug regimens in antiretroviral-naïve patients, poster 38. Abstr. 8th Int. Wkshp. Clin. Pharmacol. HIV Ther., 16 to 18 April 2007, Budapest, Hungary.
3. DART Trial Team. 2009. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 375:123-131.
4. Dickinson, L., L. Robinson, J. Tjia, S. Khoo, and D. Back. 2005. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 829:82-90.
5. Else, L., T. Mahungu, Z. Cuthbertson, C. Smith, D. Podlekareva, P. Hay, U. B. Dragsted, S. Khoo, M. Johnson, D. Back, and M. Youle. 2008 An open-label multi-centre pilot study evaluating the pharmacokinetics of co-administered lopinavir and nevirapine in HIV-infected adults. The NRTI-sparing study, abstr. P250. Abstr. 9th Int. Congr. Drug Ther. HIV Infect., Glasgow, United Kingdom, November 2008.
6. Gathe, J., B. A. da Silva, D. E. Cohen, M. R. Loutfy, D. Podzamczer, R. Rubio, S. Gibbs, T. Marsh, C. Naylor, L. Fredrick, and B. Bernstein. 2009. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J. Acquir. Immune Defic. Syndr. 50:474-481.
7. Gilks, C. F., S. Crowley, R. Ekpini, S. Gove, J. Perriens, Y. Souteyrand, D. Sutherland, M. Vitoria, T. Guerma, and K. De Cock. 2006. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505-510.
8. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
9. Klein, C., Y. Cai, Y. Chiu, S. Causemaker, T. Doan, T. Podsadecki, B. Bernstein, and G. Hanna. 2006. Pharmacokinetics of lopinavir and ritonavir after multiple dose administration of lopinavir/ritonavir tablet co-administered with efavirenz, abstr. P286. Abstr. 8th Int. Congr. Drug Ther. HIV Infect., Glasgow, United Kingdom, 12 to 16 November 2006.
10. Klein, C., J. Ng, Y. L. Chiu, P. M. Diderichsen, B. da Silva, B. Bernstein, and W. Awni. 2008. Population pharmacokinetic/pharmacodynamic analyses of lopinavir and ritonavir in subjects receiving the tablet formulation, abstr. P245. Abstr. 9th Int. Congr. Drug Ther. HIV Infect., Glasgow, United Kingdom, November 2008.
11. Klein, C., T. Zhu, Z. Chiu, T. Doan, G. Hanna, W. Awni, and S. Brun. 2005. Effect of efavirenz on lopinavir/ritonavir pharmacokinetics from a new tablet formulation, poster PE4.3/2. European AIDS Clinical Society, Paris, France.
12. Klein, C. E., Y. L. Chiu, W. Awni, T. Zhu, R. S. Heuser, T. Doan, J. Breitenbach, J. B. Morris, S. C. Brun, and G. J. Hanna. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410.
13. la Porte, C., D. Back, T. Blaschke, C. Boucher, C. Fletcher, C. Flexner, J. Gerber, A. Kashuba, J. Schapiro, and D. Burger. 2006. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antivir. Ther. 3:4-14.
14. Molto, J., M. J. Barbanoj, C. Miranda, A. Blanco, J. R. Santos, E. Negredo, J. Costa, P. Domingo, B. Clotet, and M. Valle. 2008. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin. Pharmacokinet. 47:681-692.
15. Ng, J., C. Klein, J. Xiong, Y.-L. Chiu, T. Doan, C. Rolle, C. Holas, R. Stryker, and B. Bernstein. 2008. Lopinavir/ritonavir (LPV/r) 500/125 mg BID plus efavirenz approximate the pharmacokinetic exposure of LPV/r 400/100 mg BID administered alone in healthy adult subjects, abstr. 765. Abstr. 15th Conf. Retroviruses Opportun. Infect., Boston, MA.
16. Stek, A. M., M. Mirochnick, E. Capparelli, B. M. Best, C. Hu, S. K. Burchett, C. Elgie, D. T. Holland, E. Smith, R. Tuomala, A. Cotter, and J. S. Read. 2006. Reduced lopinavir exposure during pregnancy. AIDS 20:1931-1939.